Fig. 3From: Add-on multiple submucosal injections of the RNA oligonucleotide GUT-1 to anti-TNF antibody treatment in patients with moderate-to-severe ulcerative colitis: an open-label, proof-of concept studyInduction of clinical remission by add-on GUT-1. A Rates of clinical remission at baseline (BL), week 2, 4 and 6. B % changes from baseline in the mean mMS, Endoscopic Subscore, SFS and RBS. Means are shownBack to article page